RGNX Regenxbio
- 14.050
- +0.290+2.11%
Regenxbio News
Assessing Regenxbio: Insights From 4 Financial Analysts
In the latest quarter, 4 analysts provided ratings for Regenxbio (NASDAQ:RGNX), showcasing a mix of bullish and bearish perspectives.The following table provides a quick overview of their recent ratin
REGENXBIO Initiated at Buy by Goldman Sachs
REGENXBIO Initiated at Buy by Goldman Sachs
Express News | Regenxbio (RGNX.US) received its first coverage from Goldman Sachs, with a buy rating and a target price of $38.00.
Goldman Sachs Initiates Coverage On Regenxbio With Buy Rating, Announces Price Target of $38
Goldman Sachs analyst Paul Choi initiates coverage on Regenxbio (NASDAQ:RGNX) with a Buy rating and announces Price Target of $38.
Goldman Sachs Initiates Regenxbio(RGNX.US) With Buy Rating, Announces Target Price $38
Goldman Sachs analyst Paul Choi initiates coverage on $Regenxbio(RGNX.US)$ with a buy rating, and sets the target price at $38.According to TipRanks data, the analyst has a success rate of 52.1% and a
REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
ROCKVILLE, Md., June 5, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 202
It Looks Like REGENXBIO Inc.'s (NASDAQ:RGNX) CEO May Expect Their Salary To Be Put Under The Microscope
PTC Therapeutics Rallies 18% on EU Authorization Update for Translarna
Regenxbio(RGNX.US) Officer Sells US$237.22K in Common Stock
$Regenxbio(RGNX.US)$ Officer Mills Kenneth T. sold 15,000 shares of common stock on May 14, 2024 at an average price of $15.8148 for a total value of $237.22K.Source: Announcement What is statement of
Evaluating Regenxbio: Insights From 9 Financial Analysts
During the last three months, 9 analysts shared their evaluations of Regenxbio (NASDAQ:RGNX), revealing diverse outlooks from bullish to bearish.In the table below, you'll find a summary of their rece
REGENXBIO Price Target Raised to $38.00/Share From $36.00 by HC Wainwright & Co.
REGENXBIO Price Target Raised to $38.00/Share From $36.00 by HC Wainwright & Co.
REGENXBIO Is Maintained at Buy by HC Wainwright & Co.
REGENXBIO Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : Maintain the Regenxbio (RGNX.US) rating, adjust from buy to buy rating, and adjust the target price from $36.00 to $38.00.
HC Wainwright & Co. : Maintain the Regenxbio (RGNX.US) rating, adjust from buy to buy rating, and adjust the target price from $36.00 to $38.00.
HC Wainwright & Co. Maintains Buy on Regenxbio, Raises Price Target to $38
HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and raises the price target from $36 to $38.
Regenxbio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 134.42% HC Wainwright & Co. $36 → $38 Maintains Buy 04/12/2024 146.76% Stifel → $40 Maintains B
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), PepGen Inc. (PEPG) and RegenXBio (RGNX)
REGENXBIO Inc. (NASDAQ:RGNX) Shares Could Be 43% Below Their Intrinsic Value Estimate
Key Insights REGENXBIO's estimated fair value is US$27.02 based on 2 Stage Free Cash Flow to Equity REGENXBIO's US$15.44 share price signals that it might be 43% undervalued Analyst price target
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., May 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: BofA Securities Health Care Conference 2
Buy Rating Affirmed for RegenXBio Amid Promising Drug Developments and Solid Financials
HHS Panel to Vote in Nov. on DMD Screening for Newborns
Analysis
Price Target
No Data
